Conditions: Carcinoma, Renal Cell
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 120
Healthy volunteers: no

Brief summary:
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year.

Detailed description:

Arms:
arm 1: Sunitinib malate starting dose 37.5 mg daily continuous daily schedule

Interventions: intervention 1: Sunitinib malate
Intervention descriptions: intervention 1: Sunitinib malate starting dose 37.5 mg daily continuous daily schedule

Protocol document: